Autoantigen‐selected B cells are bystanders in spontaneous T cell‐driven experimental autoimmune hepatitis

Autoreactive B cells are considered pathogenic drivers in many autoimmune diseases; however, it is not clear whether autoimmune B cells are invariably pathogenic or whether they can also arise as bystanders of T cell-driven autoimmune pathology. Here, we studied the B cell response in an autoantigen- and CD4+ T cell-driven model of autoimmune hepatitis (AIH), the Alb-iGP_Smarta mouse in which expression of a viral model antigen (GP) in hepatocytes and its recognition by GP-specific CD4+ T cells causes spontaneous AIH-like disease. T cell-driven AIH in Alb-iGP_Smarta mice was marked by autoantibodies and hepatic infiltration of plasma cells and B cells, particularly of isotype-switched memory B cells, indicating antigen-driven selection and activation. Immunosequencing of B cell receptor repertoires confirmed B cell expansion selectively in the liver, which was most likely driven by the hepatic GP model antigen, as indicated by branched networks of connected sequences and elevated levels of IgG antibodies to GP. However, intrahepatic B cells did not produce increased levels of cytokines and their depletion with anti-CD20 antibody did not alter the CD4+ T cell response in Alb-iGP_Smarta mice. Moreover, B cell depletion did not prevent spontaneous liver inflammation and AIH-like disease in Alb-iGP_Smarta mice. In conclusion, selection and isotype-switch of liver-infiltrating B cells was dependent on the presence of CD4+ T cells recognizing liver antigen. However, recognition of hepatic antigen by CD4+ T cells and CD4+ T cell-mediated hepatitis was not dependent on B cells. Thus, autoreactive B cells can be bystanders and need not be drivers of liver inflammation in AIH.

[1]  M. Gisslén,et al.  COVID‐19 is associated with bystander polyclonal autoreactive B cell activation as reflected by a broad autoantibody production, but none is linked to disease severity , 2022, Journal of medical virology.

[2]  M. Altfeld,et al.  Inflammatory type 2 conventional dendritic cells contribute to murine and human cholangitis. , 2022, Journal of hepatology.

[3]  A. Spoorenberg,et al.  B Cell Involvement in the Pathogenesis of Ankylosing Spondylitis , 2021, International journal of molecular sciences.

[4]  M. Manns,et al.  Anti-CD20 Therapy Alters the Protein Signature in Experimental Murine AIH, but Not Exclusively towards Regeneration , 2021, Cells.

[5]  J. Herkel,et al.  Failure of thymic deletion and instability of autoreactive Tregs drive autoimmunity in immune-privileged liver , 2021, JCI insight.

[6]  J. Gommerman,et al.  B cell depletion therapies in autoimmune disease: advances and mechanistic insights , 2020, Nature Reviews Drug Discovery.

[7]  A. Lohse,et al.  Next‐Generation Immunosequencing Reveals Pathological T‐Cell Architecture in Autoimmune Hepatitis , 2020, Hepatology.

[8]  N. Pochet,et al.  Checkpoint Receptor TIGIT Expressed on Tim-1+ B Cells Regulates Tissue Inflammation. , 2020, Cell reports.

[9]  J. Herkel,et al.  Autoimmune hepatitis: Possible triggers, potential treatments. , 2020, Journal of hepatology.

[10]  Tinghong Ye,et al.  Critical roles of conventional dendritic cells in autoimmune hepatitis via autophagy regulation , 2020, Cell Death & Disease.

[11]  M. Manns,et al.  Efficacy of rituximab in difficult-to-manage autoimmune hepatitis: Results from the International Autoimmune Hepatitis Group , 2019, JHEP reports.

[12]  C. Mack,et al.  The Contribution of B Cells in Autoimmune Liver Diseases , 2019, Seminars in Liver Disease.

[13]  J. Cyster,et al.  B Cell Responses: Cell Interaction Dynamics and Decisions , 2019, Cell.

[14]  S. Opat,et al.  Anti-CD20 monoclonal antibodies: reviewing a revolution , 2018, Human vaccines & immunotherapeutics.

[15]  M. Fujimoto,et al.  BAFF inhibition attenuates fibrosis in scleroderma by modulating the regulatory and effector B cell balance , 2018, Science Advances.

[16]  M. Manns,et al.  Autoimmune hepatitis , 2018, Nature Reviews Disease Primers.

[17]  Rohit Loomba,et al.  Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity , 2017, Nature.

[18]  D. Kono,et al.  The multiple pathways to autoimmunity , 2017, Nature Immunology.

[19]  A. Verkman,et al.  Mechanisms of Autoantibody-Induced Pathology , 2017, Front. Immunol..

[20]  Donald W. Lee,et al.  BRILIA: Integrated Tool for High-Throughput Annotation and Lineage Tree Assembly of B-Cell Repertoires , 2017, Front. Immunol..

[21]  L. Kappos,et al.  Cocapture of cognate and bystander antigens can activate autoreactive B cells , 2017, Proceedings of the National Academy of Sciences.

[22]  D. Parker,et al.  CD40L is transferred to antigen‐presenting B cells during delivery of T‐cell help , 2017, European journal of immunology.

[23]  K. Abe,et al.  Interleukin-21 plays a critical role in the pathogenesis and severity of type I autoimmune hepatitis , 2016, SpringerPlus.

[24]  F. Alvarez,et al.  AUTOIMMUNE, CHOLESTATIC AND BILIARY DISEASE Depletion of B Cells Induces Remission of Autoimmune Hepatitis in Mice Through Reduced Antigen Presentation and Help to T Cells , 2015 .

[25]  Y. Chu,et al.  B cells expressing CD11b effectively inhibit CD4+ T‐cell responses and ameliorate experimental autoimmune hepatitis in mice , 2015, Hepatology.

[26]  A. Radbruch,et al.  Bortezomib Plus Continuous B Cell Depletion Results in Sustained Plasma Cell Depletion and Amelioration of Lupus Nephritis in NZB/W F1 Mice , 2015, PloS one.

[27]  Ping Shen,et al.  Antibody-independent functions of B cells: a focus on cytokines , 2015, Nature Reviews Immunology.

[28]  Mikhail Shugay,et al.  MiXCR: software for comprehensive adaptive immunity profiling , 2015, Nature Methods.

[29]  E. Rosser,et al.  Regulatory B cells: origin, phenotype, and function. , 2015, Immunity.

[30]  M. Manns,et al.  Intrahepatic regulatory T cells in autoimmune hepatitis are associated with treatment response and depleted with current therapies. , 2014, Journal of hepatology.

[31]  Yanfang Jiang,et al.  Tfh and plasma cells are correlated with hypergammaglobulinaemia in patients with autoimmune hepatitis , 2014, Liver international : official journal of the International Association for the Study of the Liver.

[32]  R. Sobel,et al.  MHC class II–dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies , 2013, The Journal of experimental medicine.

[33]  Johannes E. Schindelin,et al.  Fiji: an open-source platform for biological-image analysis , 2012, Nature Methods.

[34]  D. Gray,et al.  B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6–producing B cells , 2012, The Journal of experimental medicine.

[35]  G. Ahlenstiel,et al.  Identification of CD4 T-cell epitopes in soluble liver antigen/liver pancreas autoantigen in autoimmune hepatitis. , 2008, Gastroenterology.

[36]  Kerstin Amann,et al.  The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis , 2008, Nature Medicine.

[37]  R. Tisch,et al.  Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice , 2007, Proceedings of the National Academy of Sciences.

[38]  M. Hussain,et al.  Polyclonal T-cell responses to cytochrome P450IID6 are associated with disease activity in autoimmune hepatitis type 2. , 2006, Gastroenterology.

[39]  M. Shlomchik,et al.  Antigen-Specific B Cells Are Required as APCs and Autoantibody-Producing Cells for Induction of Severe Autoimmune Arthritis1 , 2005, The Journal of Immunology.

[40]  J. Monroe,et al.  Incomplete Activation of CD4 T Cells by Antigen-Presenting Transitional Immature B Cells: Implications for Peripheral B and T Cell Responsiveness1 , 2003, The Journal of Immunology.

[41]  G. Bellomo,et al.  Liver/kidney microsomal antibody type 1 targets CYP2D6 on hepatocyte plasma membrane , 2000, Gut.

[42]  R. Tisch,et al.  B lymphocytes are critical antigen-presenting cells for the initiation of T cell-mediated autoimmune diabetes in nonobese diabetic mice. , 1998, Journal of immunology.

[43]  G. Gerken,et al.  Autoreactive CD4+ LKM‐specific and anticlonotypic T‐cell responses in LKM‐1 antibody‐positive autoimmune hepatitis , 1996, Hepatology.

[44]  K. Ishak,et al.  Histological grading and staging of chronic hepatitis. , 1995 .

[45]  C. Coffin,et al.  Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy. , 2013, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[46]  Gábor Csárdi,et al.  The igraph software package for complex network research , 2006 .